The Senate Judiciary Committee today held a hearing on the Creating and Restoring Equal Access to Equivalent Samples Act, AHA-supported legislation that targets anticompetitive behaviors used to block and delay entry of generic drugs. The bipartisan legislation would allow a generic drug manufacturer facing one of these delay tactics to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Testifying at the hearing were representatives from the Edwin Meese III Center for Legal and Judicial Studies; Institute for Innovation Law; Covington & Burling LLP; Amneal Pharmaceuticals; Consumers Union; and American College of Physicians.